Tetranectin-specific monoclonal antibodies (Feinstein Institute for Medical Research)

N/A

Report date: 2025/01/26 17:26:56

Base Information

Drug NameTetranectin-specific monoclonal antibodies (Feinstein Institute for Medical Research)
Drug Alias Nameanti-HMGB-1 mab (Feinstein Institute for Medical Research)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionHigh Mobility Group Protein B1 inhibitors
TargetsHigh Mobility Group Protein B1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Sepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFeinstein Institute For Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesFeinstein Institute For Medical Research
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Sepsis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A